观察紫杉醇联合奈达铂治疗晚期宫颈癌的疗效

摘要

目的：观察紫杉醇联合奈达铂治疗晚期宫颈癌的疗效及毒副反应。方法34例晚期宫颈癌患者，给予紫杉醇135～175 mg/m2静脉滴注1次/d，奈达铂80～100 mg/m2静脉滴注2次/d，21天为1周期，至少连用2周期后以WHO评价标准评价疗效和毒副反应。结果全部病例均可参加疗效评定。34例中CR7例，PR15例，总有效率（RR）64.71％，SD9例，PD3例。毒副反应主要为骨髓抑制，以白细胞及血小板减少多见，其次为胃肠道反应，以恶心、呕吐多见。结论紫杉醇联合奈达铂治疗晚期宫颈癌，疗效确切，不良反应较少，安全性较高。%Objective To observe nida, paclitaxel plus cisplatin in the treatment of advanced cervical cancer curative effect and adverse reaction. Methods 34 patients with advanced cervical cancer, to give 135 to 175 mg/m2 taxol intravenous drip d1, nida's platinum 80 to 100 mg/m2 intravenous drip two days, 21 days to 1 cycle, stay on at least two cycle to the WHO criteria evaluation of curative effect and adverse reaction. Results All cases are in curative effect evaluation. Shape of the 34 cases, PR15 cases, total effective rate (RR) and 64.71% SD9 example, PD3 cases. Mainly in bone marrow suppression of adverse reaction to white blood cells and thrombocytopenia, followed by gastrointestinal reaction, see more with nausea and vomiting. Conclusion nida, paclitaxel plus cisplatin treatment of advanced cervical cancer, curative effect, less adverse reaction, high security.